Ziyuglycoside II 是从Sanguisorba officinalisL. 中提取的三萜皂苷化合物。Ziyuglycoside II 诱导活性氧 (ROS) 产生和凋亡 (apoptosis)。 具有抗炎和抗癌作用。
生物活性 | Ziyuglycoside II is a triterpenoid saponin compound extracted fromSanguisorba officinalisL.. Ziyuglycoside II inducesreactive oxygen species(ROS) production andapoptosis. Anti-inflammation and anti-cancer effect[1]. |
体外研究 (In Vitro) | Ziyuglycoside II (10-60 μM; 24 h and 48 h) inhibits MDA-MB-435 cells growth in a dose-dependent manner. The IC50of Ziyuglycoside II at 24 h and 48 h is 5.92 μM and 4.74 μM, respectively[1]. Ziyuglycoside II (5-25 μM) induces G0/G1 and S phase arrest in MDA-MB-435 cells at 24 h[1]. Ziyuglycoside II (5-25 μM; 24 hours) significantly increases apoptotic rate of MDA-MB-435 cells[1]. Ziyuglycoside II (5-25 μM; 24 hours) increases expressions of both p53 and p21 in MDA-MB-435 cells, which effect is dose-dependent[1].
Cell Viability Assay[1] Cell Line: | MDA-MB-435 cells | Concentration: | 10, 20, 30, 40, 50, 60 μM | Incubation Time: | 24 hours and 48 hours | Result: | The IC50at 24 h and 48 h was 5.92 μM and 4.74 μM, respectively. |
Cell Cycle Analysis[1] Cell Line: | MDA-MB-435 cells | Concentration: | 5, 10, 25 μM | Incubation Time: | 24 hours | Result: | Induced G0/G1 and S phase arrest. |
Apoptosis Analysis[1] Cell Line: | MDA-MB-435 cells | Concentration: | 5, 10, 25 μM | Incubation Time: | 24 hours | Result: | The apoptotic rate was significantly increased in comparison to that of the control. |
Western Blot Analysis[1] Cell Line: | MDA-MB-435 cells | Concentration: | 5, 10, 25 μM | Incubation Time: | 24 hours | Result: | Treatment resulted in increased expressions of both p53 and p21. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
结构分类 | |
来源 | - Plants
- Rosaceae
- Sanguisorba officinalisLinn.
|
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | -20°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
溶解性数据 | In Vitro: DMSO : 50 mg/mL(82.67 mM;Need ultrasonic) 配制储备液 1 mM | 1.6534 mL | 8.2671 mL | 16.5341 mL | 5 mM | 0.3307 mL | 1.6534 mL | 3.3068 mL | 10 mM | 0.1653 mL | 0.8267 mL | 1.6534 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month (protect from light)。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: 0.83 mg/mL (1.37 mM); Suspended solution; Need ultrasonic
此方案可获得 0.83 mg/mL (1.37 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例,取 100 μL 8.3 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: 0.83 mg/mL (1.37 mM); Suspended solution; Need ultrasonic
此方案可获得 0.83 mg/mL (1.37 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。 以 1 mL 工作液为例,取 100 μL 8.3 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 0.83 mg/mL (1.37 mM); Clear solution
此方案可获得 ≥ 0.83 mg/mL (1.37 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 8.3 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|